DOI:
10.1055/s-00000017
Experimental and Clinical Endocrinology & Diabetes
LinksClose Window
References
Zheng SL, Roddick AJ, Aghar-Jaffar R. et al.
Association between use of sodium-glucose cotransporter 2 inhibitors,
glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with
all-cause mortality in patients with type 2 diabetes: a systematic review and
meta-analysis.
JAMA 2018;
319: 1580-1591.
DOI: 10.1001/jama.2018.3024.
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.